对抗IL-17A可减少血管炎症和减轻氧化应激形成,但不能显著改善一周安二醇治疗引起的血管功能障碍
Rebecca Jung1,2, Annika Lehmann1,2, Tanja Knopp1,2
1Center for Cardiology-Cardiology I, University Medical Center Mainz, 55131 Mainz, Germany.
Antioxidants (Basel, Switzerland)
|February 27, 2026
概括
介素-17A (IL-17A) 阻断在小鼠中部分降低了血管早期炎症和来自血管素II (Ang II) 的氧化应激. 然而,它并没有防止血管功能障碍,这表明对于自身免疫相关的心血管问题需要联合治疗.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 血管生物学 血管生物学
背景情况:
- 促炎性细胞因子介素-17A (IL-17A) 驱动血管炎症和功能障碍,将自身免疫性疾病与心血管并发症联系起来.
- 缺少IL-17A可以减轻长期血管炎症和高血压,在血管素II (Ang II) 暴露下.
- 早期的血管功能障碍,一个潜在的治疗窗口,仍然对IL-17A的作用缺乏研究.
研究的目的:
- 研究IL-17A对抗对早期血管功能障碍和Ang II诱导的炎症的影响.
- 为了确定是否准IL-17A或它的受体 (IL-17RA) 可以减轻早期的血管变化.
主要方法:
- 缺乏IL-17RA的小鼠和野生型小鼠被用Ang II治疗了一周.
- 评估了系统性氧化应激,血管功能和炎症细胞透.
- C57BL/6J小鼠接受了与Ang II治疗同时进行的抗IL-17A治疗.
主要成果:
- 无论是IL-17RA缺乏症还是抗IL-17A疗法,在Ang II暴露一周后都减轻了氧化应激和血管炎症.
- 这些干预措施并没有显著地防止Ang II诱导的血管功能障碍在这个早期的时间点开始.
- 在IL-17RA或IL-17A对抗作用时,观察到Ang II诱导的血管效应的部分减少.
结论:
- 对抗IL-17RA或IL-17A只能部分减弱早期Ang II诱导的血管效应.
- 在具有血管病理的IL-17A驱动的自身免疫疾病中,单独的抗炎疗法可能不足.
- 综合方法,包括具有直接血管保护作用的药物,可能是有效干预的必要条件.
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Antihypertensive Drugs: Direct Renin Inhibitors
1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
T Cell Types and Functions
2.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
511
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
511


